HELPLINE
For decades, mesothelioma has been widely understood as a disease that primarily affects older men with a history of occupational asbestos exposure. While this remains true in many cases, emerging research is challenging that long-held perception and expanding what both patients and healthcare providers should know about this rare and aggressive cancer. Each year, approximately…
In this episode of Meso TV, our Director of Patient Services, Julie, talks with Dr. Timothy Yap from MD Anderson Cancer Center about the VT3989 clinical trial for mesothelioma. He explains what this new treatment is, how it works, and what it could mean for patients.VT3989 is a YAP/TEAD inhibitor,…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 26th in Philadelphia, Pennsylvania. This panel is moderated by patient Jessica Blackford-Cleeton and includes mesothelioma patients who have been on or are currently on clinical trials.This panel discussion features mesothelioma patients who are currently participating in,…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 26th in Philadelphia, Pennsylvania. This panel includes Jason Foster, MD, from the University of Nebraska, Hedy Kindler, MD, from the University of Chicago, Michael Offin, MD, from Memorial Sloan Kettering Cancer Center, and Georgios Karagkounis, MD,…
Our Patient Services Director, Julie White, RN, BSN, OCN, sits down with Aaron Mansfield, MD. Dr. Mansfield is a medical oncologist and researcher at the Mayo Clinic in Rochester, Minnesota. He discusses multimodality clinical trials with Julie. Our SponsorsMesoTV is a program by the Mesothelioma Applied Research Foundation. This program is…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 26th in Philadelphia, Pennsylvania. Dean Fennell, FRCP, PhD, from University of Leicester presents on what is new in clinical trials.This presentation provides an up-to-date overview of the latest developments in clinical trials for mesothelioma, offering patients…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 26th in Philadelphia, Pennsylvania. Kevin Blyth, MD, from University of Glasgow presents on Imaging in the Future with AI. This presentation explores how artificial intelligence (AI) is transforming medical imaging for mesothelioma diagnosis, treatment planning, and…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 25th in Philadelphia, Pennsylvania. This panel includes Melina Marmarelis, MD from University of Pennsylvania, Mehmet Altan, MD, from MD Anderson Cancer Center, Adam Bograd, MD, from Swedish Health, and Michael Offin, MD, from Memorial Sloan Kettering…
The Mesothelioma Applied Research Foundation announced its latest research grant recipients, awarding a total of $300,000 at the International Symposium on Malignant Mesothelioma in Philadelphia on October 25th. This brings the Foundation’s total funding for mesothelioma research to $12.1 million, thanks to generous donations. If you’d like to support this…
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental drug, VT3989, an “Orphan Drug Designation” (ODD) to treat mesothelioma, a rare and aggressive form of cancer.VT3989 is a TEAD inhibitor. It works by blocking…
